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Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence 
for Superiority of Tetracyclines for Therapy 
Robert C. Holman,1 Christopher D. Paddock,2 
Aaron T. Curns,1 John W. Krebs,2 
Jennifer H. McQuiston,2 and James E. Childs2 
1 Office of the Director and 2Viral and Rickettsial Zoonoses Branch, 
Division of Viral and Rickettsial Diseases, National Center for 
Infectious Diseases, Centers for Disease Control and Prevention, 
US Department of Health and Human Services, Atlanta, Georgia 
Epidemiologic and clinical characteristics of fatal and nonfatal cases of Rocky Mountain 
spotted fever (RMSF) were compared to identify risk factors for death caused by this disease. 
Confirmed and probable RMSF cases reported through US national surveillance for 1981- 
1998 were analyzed. Among 6388 RMSF patients, 213 died (annual case-fatality rate, 3M; 
range, 4.9 9c in 1982 to 1.1 % in 1996). Use of tetracycline-class antibiotics for treatment of 
RMSF increased significantly in the 1990s, compared with use in the 1980s. Older patients, 
patients treated with chloramphenicol only, patients for whom tetracycline antibiotics were 
not the primary therapy, and patients for whom treatment was delayed ^5 days after the 
onset of symptoms were at higher risk for death. Although the case-fatality rate was lower in 
the 1990s than in the 1980s, risk factors for fatal RMSF were similar. Despite the availability 
of effective antibiotics, RMSF-related deaths continue to occur because of delayed diagnosis 
and failure to use appropriate therapy. 
Rocky Mountain spotted fever (RMSF), an acute febrile ill- 
ness caused by infection with Rickettsia rickettsii, is the most 
frequently reported fatal tickborne disease in the United States 
[1]. Annual case-fatality rates (CFRs) for RMSF have ranged 
from 296 to 18% since chloramphenicol and tetracycline-class 
antibiotics became available, during the late 1940s [1-8]. 
Recent reports indicate that annual CFRs for RMSF declined 
during the 1980s and into the early 1990s [1, 9, 10]. The factor 
or factors contributing to these declines are unknown. However, 
in the 1990s, treatment recommendations, especially for therapy 
for young children, were modified to encourage the use of tetra- 
cycline-class drugs as primary therapy for RMSF [1,11-13]. 
Several studies have analyzed the epidemiologic and clinical 
characteristics associated with RMSF to determine risk factors 
for fatal disease [1,4,5, 8,14]. Studies evaluating fatal and non- 
fatal cases of RMSF that occurred from the mid-1970s through 
the early 1990s have identified older patient age, black race, 
delay or lack of treatment, and failure to treat with a tetracycline 
antibiotic, individually or in combination, as risk factors for 
death [1, 2, 4, 5, 14-17]. Other studies evaluated probable and 
confirmed cases of RMSF and also included many cases that 
were unconfirmed by laboratory testing [1,5, 17]. In the present 
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study, we evaluated and compared epidemiologic and clinical 
characteristics of fatal RMSF cases with those for nonfatal 
RMSF cases during 1981-1998 in the United States. 
Methods 
RMSF cases were identified from RMSF surveillance case report 
forms submitted to the Centers for Disease Control and Prevention 
(CDC) by state health departments and private physicians [1, 9]. 
Confirmed and probable cases with known outcomes (fatal or nonfa- 
tal) that were reported during 1981-1998 were selected for this 
study. A classification of "confirmed" RMSF required signs and 
symptoms compatible with disease (e.g., fever, headache, and rash) 
and at least 1 confirmatory laboratory finding. Criteria for labora- 
tory confirmation based on serologic testing included a ^4-fold 
change in titer of antibody to R. rickettsii antigen between acute- 
and convalescent-phase serum specimens, measured by indirect 
immunofluorescence assay, complement fixation, latex aggluti- 
nation, microagglutination, or indirect hemagglutination assay [9]. 
In addition, criteria for laboratory confirmation of RMSF included 
production of an amplicon of DNA using polymerase chain reaction 
assays with specific primers for/?, rickettsii; demonstration of rick- 
ettsial antigens by immunostaining of biopsy or autopsy tissues; or 
isolation of R. rickettsii from clinical specimens. A "probable" 
RMSF case was defined by clinically compatible symptoms and 
a single titer, measured by indirect immunofluorescence assay, of 
^64; a single complement fixation titer of ^16; or another sup- 
portive serologic finding (^4-fold rise in titer or a single titer of 
^320, reactive with Proteus OX-19 or OX-2 antigens [Weil- 
Felix test], or a single titer of 5=128, measured by latex aggluti- 
nation, indirect hemagglutination assay, or microagglutination 
test). Case reports that did not meet these criteria were considered 
to be "unconfirmed." 
Demographic characteristics and clinical information for patients 
with fatal RMSF and patients with nonfatal RMSF were analyzed 
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for the period 1981-1998 and for 2 separate 9-year intervals, 
1981-1989 and 1990-1998. Characteristics for analyses included 
patient age, type of antibiotic treatment, geographic region of resi- 
dence, clinical signs and symptoms at presentation, and number of 
days from onset of illness to treatment (onset-to-treatment interval). 
CFRs were calculated for these characteristics, and comparisons 
between patients with fatal RMSF and those with nonfatal RMSF 
were made using odds ratios (ORs) and 95 9c confidence intervals 
(CIs). Age groups included patients ^ 0 years and ^ 40 years old 
and, for additional analysis, groups of patients ^ , 5-9, 10-19, 
20-29, 30-39, 40-49, 50-59, 60-69, and ^ 70 years old. Treat- 
ment therapies were grouped by use of any tetracycline without 
chloramphenicol (tetracyclines only), chloramphenicol without a 
tetracycline (chloramphenicol only), both a tetracycline and chlor- 
amphenicol (both), and neither a tetracycline nor chloramphenicol 
(neither). Geographic regions of residence were the US Bureau of 
the Census regions (i.e., Northeast, Midwest, South, and West). 
The clinical triad for RMSF was defined as the presence of fever 
and rash and a history of tick attachment [3]. For patients treated 
with chloramphenicol or tetracycline, onset-to-treatment intervals 
were grouped as ^ days and ^ 5 days for analysis as a risk factor. 
Onset-to-treatment intervals for patients with fatal RMSF and 
patients with nonfatal RMSF were also compared by the Wilcoxon 
rank sum test [18]. To further evaluate antibiotic use, the difference 
in the frequency of use of tetracyclines and of chloramphenicol was 
compared by means of the ^  test. Hospitalization of patients was 
examined as a measure of severity of illness. 
Multivariate logistic regression was done for the periods 1981- 
1998, 1981-1989, and 1990-1998 to further examine risk factors 
that were significantly associated with increased case fatality by 
fitting a series of hierarchical models to identify the best-fitting par- 
simonious model [19]. Risk factors were also examined separately 
for hospitalized patients and for patients with confirmed cases 
during 1981-1998. 
Results 
RMSF-associated mortality, 1981-1998. A total of 9968 
RMSF case report forms were submitted to the CDC for 1981- 
1998. Of 6573 cases that met the definition for confirmed or 
probable RMSF, whether the patient was surviving or deceased 
was specified on the case report form for 6388 (97.2*^). Con- 
firmed cases accounted for 5178 (81.19fc) of those 6388 cases. 
Cases from 46 states and the District of Columbia were reported. 
Reports were made of 213 RMSF-associated deaths in 29 states; 
189 (88^) of those patients had confirmed cases. The average 
annual CFR was 3.396 for 1981-1998 (table 1). The annual 
CFR ranged from 4.9*70 in 1982 to 1.19fcin 1996(figure 1). 
Risk factors for death from RMSF. To identify risk factors 
for death from RMSF, we compared epidemiologic and clinical 
characteristics of fatal cases of RMSF with those of nonfatal 
cases (table 1). Although most deaths (170) occurred in the 
South (figure 2), CFRs were similar across all regions of resi- 
dence. CFRs for male and for female patients were similar 
(3.3^o and 3.59fc, respectively). 
Black patients had a higher CFR (5A9o) than did white 
patients (3.3*^), although the difference was not statistically sig- 
nificant. Further examination of characteristics by race indicat- 
ed that black patients were less likely than white patients to pre- 
sent with a reported tick attachment, any rash, rash on the 
palms, clinical triad, headache, or myalgia. When the analysis 
was controlled for these factors, an association between race 
and increased risk for death was no longer seen (OR, 1.1; 95Tc 
CI, 0.5-2.3). 
The risk of death was significantly higher for patients ^40 
years old than for those ^0 years old (5.896 and 2.096, respec- 
tively; table 1). The CFRs for age groups that included patients 
^0 years old ranged from 1.896 to 2.796, whereas those for age 
groups that included patients ^40 years old ranged from 4.596 
to 7.896 (figure 3). The highest rates were among patients ^60 
years old (7.796). The median age for patients with fatal cases 
of RMSF was 45 years, compared with 28 years for patients 
with nonfatal cases (P < .001). The risk for death was also sig- 
nificantly greater for RMSF patients who did not receive tetra- 
cyclines-only treatment, for those treated with chloramphenicol 
only, and for those who did not receive treatment with either a 
tetracycline or chloramphenicol. Onset-to-treatment interval 
information was available for 4208 (75.196) of 5600 patients for 
whom specific therapy was reported. Patients with an onset-to- 
treatment interval of ^5 days had a significantly higher risk of 
death than did those with an interval of ^ days. Other risk 
factors for death included temperature of ^380 C at presentation, 
absence of headache at presentation, and absence of reported 
tick attachment. 
Trends in fatal RMSF over time. The CFR for all patients 
was lower during 1990-1998 than during 1981-1989 (2.896 
and 3.796, respectively [OR, 0.7; 9596 CI, 0.6-1.0]; table 1). 
The CFRs for male patients for the 1990s and the 1980s were 
similar (3.1 and 3.4, respectively), whereas the CFRs for female 
patients declined (2.396 and 4.396, respectively [OR, 0.5; 9596 
CI, 0.3-0.8]). CFRs for white patients and black patients were 
similar during the 1990s and 1980s; an elevated risk for death 
was seen among black patients, but this difference was not 
statistically significant. The CFR for patients ^40 years old 
was significantly lower during the 1990s than during the 1980s 
(3.996 and 7.596, respectively [OR, 0.5; 9596 CI, 0.3-0.7]), 
whereas the CFRs for patients ^0 years old did not differ sig- 
nificantly (2.1 and 2.0, respectively; figure 3). However, during 
the 1990s, the CFRs for patients 40-49 and 50-59 years old 
were similar to those for patients ^0 years old (OR, 1.3; 9596 
CI, 0.7-2.5). Older patient age, treatment with chlorampheni- 
col only, no tetracyclines-only treatment, and treatment delay 
of ^5 days were consistently associated with increased risk 
for death during the 1980s and the 1990s. Other risk factors 
for death during the 1980s included no report of tick attach- 
ment, no headache at presentation of illness, and no treatment 
with either a tetracycline or chloramphenicol. During the 1990s, 
Table 1. Characteristics of patients with Rocky Mountain spotted fever, United States, 1981-1998. 
1981-1989 1990-1998 1981-1998 
Total 142(3.7) 3684 71(2.8) 2491 213(3.3) 6175 
Sex 
Female 61(4.3) 1371 1.0 24(2.3) 1005 1.0 85(3.5) 2376 1.0 
Male 80(3.4) 2271 0.8(0.6-1.1) 47(3.1) 1446 1.4(0.8-2.2) 127(3.3) 3717 1.0(0.7-1.3) 
Age, years 
^0 53(2.0) 2566 1.0 31(2.1) 1454 1.0 84(2.0) 4020 1.0 
5=40 87(7.5) 1067 3.9(2.8-5.6) 40(3.9) 984 1.9(1.2-3.1) 127(5.8) 2051 3.0(2.2-3.9) 
Race 
White 121(3.7) 3161 1.0 59(2.8) 2071 1.0 180(3.3) 5232 1.0 
Black 13(5.1) 242 1.4(0.8-2.5) 9(5.1) 166 1.9(0.9-3.9) 22(5.1) 408 1.6(1.0-2.5) 
Region of residence 
Northeast 9(4.4) 196 1.0 2(1.2) 166 1.0 11(2.9) 362 1.0 
Midwest 13(2.5) 498 0.6(0.2-1.4) 14(4.2) 321 3.6(0.8-16.1) 27(3.2) 819 1.1(0.5-2.2) 
South 117(3.9) 2922 0.9(0.4-1.8) 53(2.6) 1954 2.3(0.5-9.3) 170(3.4) 4876 1.1(0.6-2.1) 
West 3(4.3) 67 1.0(0.3-3.8) 2(4.3) 45 3.7(0.5-26.9) 5(4.3) 112 1.5(0.5-4.3) 
Tick attachment 
Yes 68(2.9) 2242 0.6(0.4-0.9) 32(2.3) 1338 0.9(0.5-1.6) 100(2.7) 3580 0.7(0.5-1.0)b 
No 58(4.7) 1187 1.0 22(2.5) 856 1.0 80(3.8) 2043 1.0 
Symptoms 
Fever (temperature 5=38"C) 
Yes 135(3.8) 3403 2.2(0.7-7.0) 62(3.1) 1937 6.0(1.5-24.8) 197(3.6) 5340 4.0(1.6-9.8) 
No 3(1.8) 167 1.0 2(0.5) 378 1.0 5(0.9) 545 1.0 
Headache 
Yes 91(3.1) 2834 0.5(0.3-0.8) 36(2.0) 1759 0.7(0.4-1.4) 127(2.7) 4593 0.6(0.4-0.9) 
No 25(5.8) 407 1.0 11(2.7) 392 1.0 36(4.3) 799 1.0 
Myalgia 
Yes 89(3.5) 2486 1.1(0.7-2.0) 42(2.4) 1691 1.6(0.7-3.9) 131(3.0) 4177 1.3(0.8-2.0) 
No 16(3.0) 513 1.0 6(1.5) 394 1.0 22(2.4) 907 1.0 
Rash 
Yes 112(3.7) 2926 0.9(0.6-1.5) 42(2.7) 1513 1.5(0.8-2.8) 154(3.4) 4439 1.2(0.9-1.8) 
No 24(4.0) 581 1.0 14(1.8) 778 1.0 38(2.7) 1359 1.0 
Rash on palms 
Yes 54(2.9) 1796 0.7(0.5-1.1) 24(3.2) 729 1.8 (1.0-3.3)b 78(3.0) 2525 1.1(0.8-1.5) 
No 49(3.9) 1206 1.0 22(1.8) 1230 1.0 71(2.8) 2436 1.0 
Clinical triadc 
Yes 51(2.9) 1714 0.7(0.5-1.0) 21(3.0) 683 1.5(0.9-2.7) 72(2.9) 2397 0.9(0.7-1.2) 
No 69(4.3) 1534 1.0 26(2.0) 1291 1.0 95(3.3) 2825 1.0 
Treatment 
Tetracyclines only 
Yes 30(1.4) 2132 0.2(0.1-0.3) 30(1.6) 1867 0.3(0.2-0.6) 60(1.5) 3999 0.2(0.2-0.3) 
No 105(7.0) 1405 1.0 25(4.6) 519 1.0 130(6.3) 1924 1.0 
Chloramphenicol only 
Yes 67(7.7) 804 3.3(2.4-4.7) 12(7.2) 155 4.0(2.1-7.8) 79(7.6) 959 3.7(2.7-5.0) 
No 68(2.4) 2733 1.0 43(1.9) 2231 1.0 111(2.2) 4964 1.0 
Both 
Yes 18(4.4) 389 1.2(0.7-2.1) 3(3.1) 93 1.4(0.4-4.7) 21(4.2) 482 1.4(0.9-2.2) 
No 117(3.6) 3148 1.0 52(2.2) 2301 1.0 169(3.0) 5449 1.0 
Neither 
Yes 20(8.6) 212 2.7(1.7-4.5) 10(3.5) 271 1.7(0.9-3.5) 30(5.8) 483 2.1(1.4-3.2) 
No 115(3.3) 3325 1.0 45(2.1) 2123 1.0 160(2.9) 5448 1.0 
Onset-to-treatment interval, days 
K5 29(1.9) 1542 1.0 8(1.0) 790 1.0 37(1.6) 2332 1.0 
5=5 73(6.0) 1137 3.4(2.2-5.3) 24(3.8) 607 3.9(1.7-8.8) 97(5.3) 1742 3.5(2.4-5.2) 
No. of deaths 
(CFR) 
No. of deaths 
(CFR) 
NOTE. CFR, case-fatality rate; CI, confidence interval; OR, odds ratio. 
Variations in the no. of cases listed for each characteristic are due to unknown or missing responses. b Confidence limit equals 1.0 because of rounding (P < .05). 
c Fever, any rash, and tick attachment. 
Characteristic3 
No. of 
survivors 
OR 
(959c CI) 
No. of deaths 
(CFR) 
No. of 
survivors 
OR 
(959c CI) 
No. of 
survivors 
OR 
(959c CI) 
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Figure 1. Annual no. of deaths and case-fatality rate (CFR) for Rocky Mountain spotted fever cases in the United States, 1981 -1998 
other risk factors included temperature ^380C and rash on 
palms at presentation. 
Antibiotic treatment and outcome. Information on antibiotic 
treatment was provided for 5600 confirmed and probable RMSF 
cases (87.796) with a known outcome during 1981-1998. Most 
RMSF patients (66.4%) were treated with tetracyclines only; 
17.0% received chloramphenicol only, and 8.2% received both 
a tetracycline and chloramphenicol. The use of tetracyclines- 
only treatment increased in the 1990s (77.796, vs. 58^ in the 
1980s; P < .001), whereas chloramphenicol-only treatment 
declined (6.896, vs. 23^ in the 1980s; P < .001). Treatment 
with both therapies also increased in the 1990s (11.^, vs. 
3.996 in the 1980s; P< .001). 
To further evaluate the impact of chloramphenicol-only use 
among young patients, we stratified patients by age ^0 years 
and 5210 years for each 9-year period. Patients ^0 years old 
were treated only with chloramphenicol significantly more 
often than were patients ^  10 years old during the 1980s (49^ 
vs. 13^; P < .001). Chloramphenicol-only treatment during 
the 1990s remained significantly higher for those < 10 years old 
than for those ^10 years old (26.39fc vs. 2.69fc; P < .001). The 
CFR for patients < 10 years old who were treated with chloram- 
phenicol only did not change significantly in the 1990s, com- 
pared with the CFR for that group in the 1980s (4.39fc [5 out of 
115] and 2.69fc [13 out of 509], respectively [OR, 1.7; 95% CI, 
0.6-4.7]). No deaths were reported among 229 patients ^0 
years old who were treated with tetracyclines only during the 
1990s, and 1 death was reported among 599 of such patients 
during the 1980s. 
Overall, CFRs for patients in each drug treatment category did 
not differ between the 1980s and the 1990s (chloramphenicol 
only, 7.79fc and 7.29fc, respectively; tetracyclines only, 1.49fc 
and 1.69k, respectively). The CFR for patients treated only 
with chloramphenicol during 1981-1998 was greater than that 
for patients treated only with tetracyclines (7.696 vs. 1.59fc 
[OR, 5.5; 95% CI, 3.9-7.7]), a difference apparent during both 
9-year periods. The CFR for patients treated only with tetra- 
cyclines differed from that for patients who did not receive anti- 
biotic treatment (OR, 0.2; 95% CI, 0.2-0.4), whereas the CFR 
for patients treated only with chloramphenicol did not differ 
from that for patients who did not receive antibiotic treatment 
(OR, 1.3; 95% CI, 0.9-2.1). These findings were consistent for 
both time periods. CFRs for patients ^40 years old were higher 
than those for patients ^ 0 years old, both among patients treat- 
ed with chloramphenicol only and among those treated with 
tetracyclines only. Further examination of the cases of patients 
^0 years old showed that the CFR for patients treated only 
with chloramphenicol was higher than the CFR for those treated 
only with tetracyclines (2.996 and 0.296, respectively [OR, 17.8; 
95% CI, 2.8-741.3]); for patients ^10 years, a similar differ- 
ence in CFRs was seen (15^ and 1.796, respectively [OR, 
10.1; 95% CI, 6.8-14.9]). 
Among patients treated with tetracyclines only, those with 
fatal cases of RMSF had experienced a longer delay before anti- 
biotic treatment than had those with nonfatal cases (median, 6 
and4 days, respectively; P ^ .003); the same was true of patients 
treated with chloramphenicol only (median, 6 and 5 days, 
respectively; P < .001). For all RMSF patients, the median 
onset-to-treatment interval for both chloramphenicol-only and 
tetracyclines-only treatment was 5 days. Among patients treated 
^ days after diagnosis, the CFR for those treated only with 
chloramphenicol was higher than for those treated only with 
Year 
no, 
of 
deaths 
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Figure 2. Geographic distribution of reported deaths due to Rocky Mountain spotted fever in the United States, 1981-1998. County of residence 
was available for 210 of 213 reported deaths. 
tetracyclines (3.5% and 1.0%, respectively [OR, 3.7; 95% CI, 
1.7-7.9]); this difference was also noted for patients treated a>5 
days after diagnosis (12.2% and 2.5%, respectively [OR, 5.4; 
95% CI, 3.3-8.7]). 
Hospitalization, antibiotic treatment, and outcome. Hospi- 
talization occurred among 4166 (65.5%) of the 6359 RMSF 
patients for whom this information was reported during 1981- 
1998. Patients with fatal RMSF were hospitalized more often 
than patients with nonfatal RMSF (95.7% and 64.5%, respec- 
tively [OR, 12.4; 95% CI, 6.3-24.2]). The CFR for hospitalized 
patients did not differ by time period (4.8% for 1981-1989 and 
4.9% for 1990-1998, respectively). Hospitalized patients were 
more likely to be treated with tetracyclines only than with chlor- 
amphenicol only (57.8% and 23.3%, respectively; P < .001). 
The median number of days between onset of RMSF and 
treatment for hospitalized patients with fatal cases and for 
hospitalized patients with nonfatal cases was 6 and 4 days, re- 
spectively (P < .001). 
Multivariate analyses. Multiple logistic regression indi- 
cated that older patient age, onset-to-treatment interval of a>5 
days, no tetracyclines-only treatment, and chloramphenicol- 
only treatment remained significantly associated with death 
from RMSF during 1981-1998 (table 2). Risk factors remained 
the same when the analysis was restricted to patients with 
confirmed cases and to hospitalized patients (data not shown). 
For 1981-1989, the analysis showed that older patient age, 
onset-to-treatment interval of z>5 days, no tetracyclines-only 
treatment, and chloramphenicol-only treatment were significant 
risk factors. For 1990-1998, older patient age, onset-to-treat- 
ment interval of >5 days, and chloramphenicol-only treatment 
were statistically associated with fatal RMSF. 
Discussion 
This study identified older patient age, delay in treatment, 
chloramphenicol-only treatment, and treatment that did not 
involve a tetracycline antibiotic as primary therapy as risk fac- 
tors for death among RMSF patients in the United States during 
1981-1998. These findings are largely consistent with risk fac- 
tors identified individually or in combination with other epide- 
miologic and clinical characteristics in studies that examined 
RMSF deaths during the 1970s and the 1980s [1, 4, 5, 8, 14]. In 
this study, factors associated with death appeared to be consis- 
tent over time, with the following exceptions: the age for 
increased risk of death appeared to shift from patients 
h>40 
years old during the 1980s to those >s60 years old during the 
1990s, and the reported use of chloramphenicol for RMSF 
declined markedly and the use of tetracyclines increased during 
the 1990s, compared with use of these antibiotics during the 
1980s. Treatment delay, which was identified as a risk factor in 
several other studies [3, 8, 14, 20], was clearly associated with 
increased risk for death among RMSF patients. 
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Figure 3. No. of deaths and case-fatality rates (CFRs) for Rocky Mountain spotted fever cases, by age group and time period, in the United States, 
1981-1998. 
Before the discovery of RMSF-specific antibiotic therapy, -1 
of every 5 patients infected with R. rickettsii died [21]. The 
original description of chloramphenicol in 1947 [22] was 
accompanied by a report showing that this antibiotic inhibits 
the growth of R. rickettsii in embryonated eggs and in exper- 
imentally infected animals [23]. Clinical experience with use of 
chloramphenicol to treat human patients with RMSF accumu- 
lated rapidly and showed that patients treated with this antibiotic 
had relatively rapid favorable clinical responses [24, 25]. The 
use of this antibiotic and of tetracycline-class drugs, which 
were also discovered in the late 1940s, resulted in dramatic 
declines in annual CFRs over the course of the next 50 years. 
Until relatively recently, it was thought that chloramphenicol 
and tetracyclines were equally efficacious for treatment of 
RMSF; however, recent epidemiologic studies that used CDC 
case report data have suggested that RMSF patients treated with 
chloramphenicol have a greater risk of dying than do persons 
who receive tetracycline as primary therapy [1, 17]. Findings 
from the present investigation corroborate these observations 
and are notable in the context of the separate univariate and mul- 
tivariate analyses done in this study. During 1981-1998, CFRs 
for patients treated with chloramphenicol alone were signifi- 
cantly higher than CFRs for patients treated with a tetracycline. 
This observation was consistent among all patients in general, 
as well as among specialized cohorts, including the youngest 
patients (i.e., <10 years old), the most severely ill patients (i.e., 
hospitalized), and even among patients receiving specific 
therapy <5 days after onset of disease, the interval during 
which appropriate therapy has the greatest effect in reducing 
the probability of death [1, 3, 8]. 
Several in vitro studies comparing the bacteriostatic activities 
of chloramphenicol and tetracycline-class drugs against rickett- 
siae have shown that R. rickettsii is more susceptible to tetra- 
cyclines than to chloramphenicol [26, 27]. Clinical studies of 
experimentally induced RMSF in dogs showed no significant 
differences between chloramphenicol and tetracycline in alle- 
viating clinical indicators of rickettsial infection [28]; however, 
no data exist from controlled, prospective clinical trials evaluat- 
Table 2. Multivariate analysis of risk factors associated with death 
among patients with Rocky Mountain spotted fever, United States, 
1981-1998. 
Maximum 
likelihood 
Time period, risk factor estimate" SE OR (95% CI) 
1981-1998 (n = 4134) 
Age 1.6232 0.1966 5.1 (3.4-7.5) 
Treatment 
Tetracyclines only -1.0339 0.2836 0.4 (0.2-0.6) 
Chloramphenicol only 0.9527 0.2792 2.6 (1.5-4.5) 
Onset-to-treatment interval 1.0072 0.2031 2.7 (1.8-4.1) 
1981-1989 (n = 2735) 
Age 1.7971 0.2274 6.0 (3.9-9.4) 
Treatment 
Tetracyclines only -1.1087 0.3249 0.3 (0.2-0.6) 
Chloramphenicol only 0.9040 0.2993 2.5 (1.4-4.4) 
Onset-to-treatment interval 0.9120 0.2338 2.5 (1.6-3.9) 
1990-1998 (n = 1399) 
Age 1.0641 0.3929 2.9 (1.3-6.3) 
Treatment with chloramphenicol only 1.7172 0.4291 5.6 (2.4-12.9) 
Onset-to-treatment interval 1.2606 0.4156 3.5 (1.6-8.0) 
NOTE. CI, confidence interval; OR, odds ratio. 
a Calculated by multivariate logistic regression. 
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ing the relative efficacies of these drugs in humans. Chloramphen- 
icol is still appropriate therapy for RMSF in some specialized 
situations [29]. Nonetheless, despite the limitations of incom- 
plete and retrospectively collected data that are inherent to pas- 
sive reporting, the findings from this study are consistent with 
and augment data from other epidemiologic analyses describing 
the superiority of tetracyclines over chloramphenicol as primary 
therapy for RMSF. 
Changes in treatment recommendations for pediatric patients 
and the removal of the oral formulation of chloramphenicol 
from the US market in 1995 likely contributed to the decrease 
in the use of chloramphenicol during the 1990s [1, 11, 12]. In 
this study, the decline in CFR from the 1980s to the 1990s, par- 
ticularly among patients ^10 years old, may be associated in 
part with the decreased use of chloramphenicol and the increased 
use of tetracyclines for RMSF treatment in the 1990s. During the 
1990s, children < 10 years old still received chloramphenicol as 
the primary therapy for RMSF more often than all other age 
groups, reflecting a continued need for physicians to be informed 
that doxycycline is the recommended treatment for RMSF in 
children [11,12,30]. 
An increased CFR among black individuals has been reported 
in other studies [4,15]; this has been ascribed to underreporting 
of nonfatal cases and increased misdiagnosis of RMSF among 
black individuals [4] or increased incidence of a glucoses- 
phosphate dehydrogenase deficiency in this population [15]. 
However, as with earlier studies [1, 3], the present study did 
not find a significant difference between CFRs for black individ- 
uals and white individuals. 
The data from the national RMSF surveillance system have 
limitations. Although RMSF is a nationally notifiable disease 
[31], fatal and nonfatal cases of RMSF can be missed and may 
pose a diagnostic dilemma for physicians in locations where the 
disease occurs infrequently [10, 11]. Moreover, state health 
departments may have differing criteria for defining and report- 
ing RMSF cases, and some state health departments have revised 
their criteria for reporting RMSF cases to the CDC. Although 
criteria for reporting may change depending on the state, the 
specific data requested on and collected from case report forms 
have not changed since these forms were last modified, in 1981 
[5]. In this context, risk factors identified in this study and earlier 
studies are limited to those data collected on the case report form 
[1,17], which accounts in part for the consistent appearance of 
particular risk factors (e.g., specific antibiotic use, onset-to- 
treatment interval, and age). However, other risk factors (e.g., 
glucose-6-phosphate dehydrogenase deficiency) may not be 
identified in the surveillance case report form, because the form 
does not include specific queries about other medical conditions 
that may predispose patients to more-severe or fatal disease. The 
severity of the illness, which affects decisions about treatment 
and hospitalization, cannot be accurately ascertained with case 
report forms. Finally, the case report forms are not always fully 
completed and are completed with varying attention to detail. 
RMSF continues to be a potentially lethal threat throughout 
much of the United States, and recognized risk factors for total 
RMSF death are largely unchanged since the 1980s. Despite 
enhanced awareness of tickbome diseases during the 1980s and 
1990s [16, 32-34], diagnosis or treatment of RMSF may be 
delayed, and recommended treatment is not always adminis- 
tered; both of these situations may be associated with fatal con- 
sequences. Prompt treatment with tetracycline-class antibiotics 
within the first few days of onset of illness significantly reduces 
the risk of death [1,11]. CFRs for RMSF in different geographic 
regions across the United States are similar, which suggests that, 
even in the region with the highest incidence of RMSF and, pre- 
sumably, the greatest awareness of the disease (i.e., the South), 
treatment delays may occur and recommended therapy is not 
always provided. This observation suggests that, if deaths due 
to RMSF are to be further reduced in the United States, increased 
awareness and public health education regarding RMSF remain 
fundamental in achieving this goal. 
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